|
|
Дата |
|---|
| 22:21 |
| 22.10.2026 |
| 21.10.2026 |
| 20.10.2026 |
| 19.10.2026 |
| 16.10.2026 |
| 15.10.2026 |
| 14.10.2026 |
| 13.10.2026 |
| 12.10.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
1.52
|
1.54
|
2.94
|
1.465
|
3.00
|
1.53
|
|
|
7 246 315.47
|
24 244.00
|
|
4.93
|
4.96
|
4.41
|
3.91
|
4.41
|
3.95
|
|
|
2 408 679.93
|
5 472.00
|
|
4.30
|
4.52
|
3.88
|
3.88
|
4.45
|
4.41
|
|
|
45 219.73
|
179.00
|
|
3.66
|
4.00
|
3.96
|
3.86
|
3.97
|
3.87
|
|
|
34 733.70
|
112.00
|
|
3.62
|
4.79
|
3.79
|
3.66
|
3.86
|
3.74
|
|
|
149 094.63
|
208.00
|
|
3.69
|
3.92
|
4.19
|
3.74
|
4.19
|
3.80
|
|
|
167 992.69
|
161.00
|
|
3.69
|
5.70
|
3.88
|
3.81
|
3.94
|
3.86
|
|
|
22 610.03
|
109.00
|
|
3.69
|
4.72
|
4.05
|
3.845
|
4.19
|
3.90
|
|
|
109 615.19
|
216.00
|
|
3.98
|
5.70
|
4.71
|
4.04
|
4.71
|
4.04
|
|
|
184 507.54
|
679.00
|
|
4.36
|
5.62
|
4.61
|
4.465
|
4.61
|
4.465
|
|
|
55 236.84
|
143.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть